The EMA has recommended granting a marketing authorisation in the European Union (EU) for Tepezza (teprotumumab), for the treatment of adults with moderate to severe thyroid eye disease…. read more.
Amgen announced Tepezza has been approved for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease (TED) by Japan’s Ministry of Health, Labour and Welfare (MHLW)…. read more.
Amgeny announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of… read more.
Horizon Therapeutics plc announced the presentation of new data from the randomized, double-masked, placebo-controlled Phase IV clinical trial (NCT04583735) evaluating Tepezza in patients with long disease duration and… read more.
Horizon Therapeutics plc announced findings of a real-world adherence analysis of Tepezza for the treatment of TED ( Thyroid Eye Disease) at the American Academy of Ophthalmology Annual… read more.
Horizon Therapeutics plc has announced that the first patient has been enrolled in a Phase IV clinical trial evaluating the efficacy and safety of Tepezza for the treatment… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
